Cao Pharmaceuticals is currently developing their lead drug, CZ48, in Phase I clinical trials. This drug, along with their pipeline drugs, enjoy many unique advantages associated with CPT based drugs derived from a natural plant extract. Promising pipeline drugs include the redesign of a currently FDA approved CPT based drug, along with others designed with specific physiochemical properties.
Products - Unique Advantages
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusant doloremque laudantium, totam rem.